Publications

During the COVID-19 pandemic, the U.S. Government implemented policies to ease access to buprenorphine, an effective medication to treat opioid use disorder (OUD). Data from CDC’s State Unintentional Drug Overdose Reporting System (SUDORS) suggest expanded access to buprenorphine did not result in an increased proportion of opioid overdose deaths involving buprenorphine.